Pain Relief After Corneal Collagen Cross-Linking
Summary
Keratoconus is a progressive corneal ectasia that can lead to significant visual impairment and decreased quality of life. The introduction of corneal cross-linking (CXL) with riboflavin and ultraviolet-A (UVA) light has revolutionized the treatment of keratoconus by increasing corneal rigidity and arresting disease progression. The epithelium-off protocol, which induces heightened post-surgical discomfort, is the prevailing approach. Despite the success of CXL, postoperative pain is a common side effect that can negatively impact patients' quality of life and impede recovery. Pain management after CXL is essential for optimizing patient outcomes and satisfaction. Systemic painkillers, though not researched enough, may potentially aid in healing and recovery, minimizing complications and discomfort for the patient. In this study we will provide evidence-based recommendations for clinicians to optimize pain control after CXL in collaboration with pain specialists.
Timeline
- Start
- 2024-02
- Primary completion
- 2025-02
- Completion
- 2025-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gabapentin | Small molecule | 200 mg | — |
| Comparator | Oxycodone naloxone | Unknown | 5 mg | — |
| Comparator | Acetaminophen | Small molecule | 500 mg | — |
| Comparator | Ibuprofen | Small molecule | 200 mg | — |
Indications
No indication recorded.